Most Read Articles
Jairia Dela Cruz, 20 Jan 2018
Empagliflozin appears to be beneficial to type 2 diabetes (T2D) patients with established cardiovascular disease (CVD) and chronic kidney disease (CKD), yielding reductions in CV and all-cause mortality, as well as in heart failure and all-cause hospitalization compared with placebo, according to a study.
13 Feb 2018
Short-term treatment with methotrexate at >0.5 defined daily dose (8.75 mg/week) may help reduce the risk of ischaemic stroke in rheumatoid arthritis (RA) patients, while hydroxychloroquine and sulfasalazine have neutral effects, a retrospective study has found.
28 Dec 2017
Varenicline, while effective for smoking cessation, appears to significantly elevate the risk of cardiovascular hospitalization and emergency department visits, particularly for new users, a recent study shows.
29 Nov 2017
Younger children appear to be more likely to experience behavioural side effects of antiepileptic drugs (AEDs), with the likelihood increasing if children with epilepsy have baseline hyperactivity/impulsivity, a retrospective study has found.

Oral tranexamic acid safe, effective for moderate-to-severe melasma

31 Jan 2018

Oral tranexamic acid (TA) may help improve moderate-to-severe melasma with negligible side effects, according to a recent study.

Of the 44 patients included, 39 completed the study. Reduction in the modified Melasma Area and Severity Index (mMASI) score at 3 months was greater in the TA group than in the control group (49 percent vs 18 percent). Patients with severe melasma benefitted more from treatment than those with moderate melasma.

Three months after treatment cessation, reduction in mMASI score remained higher in the TA cohort compared with the baseline visit vs that in the placebo arm (26 percent vs 19 percent). There were no adverse events in either group.

This single-centre study enrolled predominantly Hispanic women. Patients with moderate-to-severe melasma received 250-mg TA or placebo capsules twice daily for 3 months and sunscreen, followed by 3 months of treatment with sunscreen only. The mMaSI score was the primary outcome measure.

In another study, researchers concluded that topical TA was effective for melasma, adding that suppression of endothelin-1 could be one of the mechanisms of action of TA on melasma. [Clin Exp Dermatol 2016;41:480-485]

A recent systematic review and meta-analysis has shown that TA is effective and safe, either alone or as an adjuvant to routine treatment modalities for melasma. [Acta Derm Venereol 2017;97:776-781]

“Melasma is a common pigmentary disorder that is often difficult to treat,” according to the investigators of the current study. “TA has emerged as a promising treatment for melasma; however, few controlled studies exist.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 20 Jan 2018
Empagliflozin appears to be beneficial to type 2 diabetes (T2D) patients with established cardiovascular disease (CVD) and chronic kidney disease (CKD), yielding reductions in CV and all-cause mortality, as well as in heart failure and all-cause hospitalization compared with placebo, according to a study.
13 Feb 2018
Short-term treatment with methotrexate at >0.5 defined daily dose (8.75 mg/week) may help reduce the risk of ischaemic stroke in rheumatoid arthritis (RA) patients, while hydroxychloroquine and sulfasalazine have neutral effects, a retrospective study has found.
28 Dec 2017
Varenicline, while effective for smoking cessation, appears to significantly elevate the risk of cardiovascular hospitalization and emergency department visits, particularly for new users, a recent study shows.
29 Nov 2017
Younger children appear to be more likely to experience behavioural side effects of antiepileptic drugs (AEDs), with the likelihood increasing if children with epilepsy have baseline hyperactivity/impulsivity, a retrospective study has found.